PREVIOUS
Newsletter # 122
In vivo studies
Methotrexate (MTX) remains a cornerstone therapy in chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, with decades of clinical experience supporting its immunomodulatory efficacy and well-characterized safety profile under appropriate monitoring. Despite its effectiveness, the ongoing search for next-generation therapies—offering improved safety, selectivity, or delivery—continues to drive innovation in this space.
In our preclinical studies, systemic administration of MTX at 3, 10, and 30 mg/kg resulted in a clear, dose-dependent reduction in oxazolone-induced ear swelling in rats. This model of immune-mediated skin inflammation shares key features with allergic contact dermatitis and provides a robust, quantifiable endpoint for assessing anti-inflammatory activity in vivo.
In our preclinical studies, systemic administration of MTX at 3, 10, and 30 mg/kg resulted in a clear, dose-dependent reduction in oxazolone-induced ear swelling in rats. This model of immune-mediated skin inflammation shares key features with allergic contact dermatitis and provides a robust, quantifiable endpoint for assessing anti-inflammatory activity in vivo.
By linking the clinical activity of methotrexate to measurable anti-inflammatory effects in this model, we offer a translationally grounded assay for evaluating novel test articles. The platform enables early-stage compound profiling and supports data-driven decision-making in the development of new therapies for inflammatory conditions.
-
Evaluate your anti-inflammatory / immunomodulator candidate in
oxazolone-induced ear swelling model
-
** indicates p ≤ 0.01, as compared to red column
*** indicates p ≤ 0.001, as compared to red column
-
Allergic contact dermatitis (ACD) is a common immune-mediated skin condition characterized by localized inflammation triggered by environmental sensitizers such as Oxazolone. Methotrexate (MTX), although not a first-line treatment for ACD, has demonstrated clinical efficacy in related inflammatory skin conditions such as chronic plaque psoriasis, lending it relevance as a benchmark immunomodulatory agent.
In the oxazolone-induced ear swelling model systemic administration of Methotrexate at 3, 10, and 30 mg/kg resulted in a dose-dependent reduction in ear thickness. This measurable anti-inflammatory effect confirms the model’s pharmacological sensitivity and supports its use as a translational platform for evaluating test articles targeting immune-driven skin inflammation.
